Literature DB >> 24613113

Hepatitis C in haemorrhagic obstetrical emergencies.

Meharunnisa Khaskheli1, Shahla Baloch1, Sumiya Farooq1.   

Abstract

OBJECTIVE: To determine the maternal health and fetal outcome in hepatitis C with obstetrical haemorrhagic emergencies. STUDY
DESIGN: An observational study. PLACE AND DURATION OF STUDY: Department of Obstetrics and Gynaecology Unit-I, Liaquat University of Medical and Health Sciences Hospital, Hyderabad, Sindh, from January 2009 to December 2010.
METHODOLOGY: All the women admitted during the study period with different obstetrical haemorrhagic emergencies were included. On virology screening, hepatitis C screening was done on all. The women with non-haemorrhagic obstetrical emergencies were excluded. Studied variables included demographic characteristics, the nature of obstetrical emergency, haemorrhagic conditions and maternal and fetal morbidity and mortality. The data was analyzed on SPSS version 20.
RESULTS: More frequent obstetrical haemorrhagic emergencies were observed with hepatitis C positive in comparison with hepatitis C negative cases including post-partum haemorrhage in 292 (80.88%) and ante-partum haemorrhage in 69 (19.11%) cases. Associated morbidities seen were disseminated intravascular coagulation in 43 (11.91%) and shock in 29 (8.03%) cases with hepatitis C positive. Fetal still birth rate was 37 (10.24%) in hepatitis C positive cases.
CONCLUSION: Frequency of maternal morbidity and mortality and perinatal mortality was high in obstetrical haemorrhagic emergencies with hepatitis C positive cases.

Entities:  

Mesh:

Year:  2014        PMID: 24613113     DOI: 03.2014/JCPSP.178181

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  1 in total

1.  Maternal HCV infection is associated with intrauterine fetal growth disturbance: A meta-analysis of observational studies.

Authors:  Qi-Tao Huang; Li-Lin Hang; Mei Zhong; Yun-Fei Gao; Man-Ling Luo; Yan-Hong Yu
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.